Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + adefovir vs entecavir
- Development stage
- Unknown
- Lead developer
- Korea University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
"Lamivudine + adefovir vs entecavir" refers to a Phase 4 randomized clinical trial (NCT00531167) sponsored by Korea University that compared two rescue strategies for patients with lamivudine-resistant chronic hepatitis B (CHB). The study evaluated the efficacy of adding adefovir dipivoxil (10 mg/day) to ongoing lamivudine (100 mg/day) therapy versus switching to entecavir monotherapy (1.0 mg/day). All three agents—lamivudine, adefovir, and entecavir—are nucleoside/nucleotide analogue antivirals that function by inhibiting the hepatitis B virus (HBV) DNA polymerase/reverse transcriptase. The trial results indicated that the combination of lamivudine and adefovir provided superior virological response rates and lower rates of genotypic resistance compared to switching to entecavir monotherapy in this specific treatment-refractory population.
- Brand names
- Epivir-HBVHepseraBaraclude
- Other names
- Adefovir Add-on vs Entecavir Switch in Lamivudine-Resistant Chronic Hepatitis B
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)POLG (Mitochondrial DNA polymerase gamma)Human nuclear DNA polymerase
Beyond the preview
Go deeper on lamivudine + adefovir vs entecavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + adefovir vs entecavir.